Lilly-backed Orbis does up to $1.4B macrocycle deal with Novo

Orbis Medicines will help Novo create macrocycles — those ring-shaped molecules that marry the best of antibodies and small molecules — for cardiometabolic diseases as part of an up to $1.4 billion alliance. The Thursday morning pact ...